SEC Comment Letter for ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Jul 3, 2018
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: July 3, 2018 · CIK: 0001513525 · Accession: 0000000000-18-020492
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220368
Letter
Mail Stop 4546 July 2, 2018 William B. Stilley, III President and Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, VA 22901
Re: Adial Pharmaceuticals, Inc. Amendment No. 6 to Registration Statement on Form S-1 Filed June 26 , 201 8 File No: 333-220368
Dear Mr. Stilley:
We have reviewed your amended registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comment appl ies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.
Notes to Financial Statements Research and Development, page F -9
1. Please revise your accounting policy disclosure here and on page F -30 to reflect your accounti ng treatment for patent related costs.
William B. Stilley Adial Pharmaceuticals, Inc. July 2, 201 8 Page 2
You may contact Rolf Sundwall at 202-551-3105 or Angela Connell at 202-551-3426 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at 202-551-2544 or Mary Beth Breslin at 202-551-3625 with any other questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 July 2, 2018 William B. Stilley, III President and Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, VA 22901 Re: Adial Pharmaceuticals, Inc. Amendment No. 6 to Registration Statement on Form S-1 Filed June 26 , 201 8 File No: 333-220368 Dear Mr. Stilley: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comment appl ies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Notes to Financial Statements Research and Development, page F -9 1. Please revise your accounting policy disclosure here and on page F -30 to reflect your accounti ng treatment for patent related costs. William B. Stilley Adial Pharmaceuticals, Inc. July 2, 201 8 Page 2 You may contact Rolf Sundwall at 202-551-3105 or Angela Connell at 202-551-3426 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at 202-551-2544 or Mary Beth Breslin at 202-551-3625 with any other questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare & Insurance cc: Leslie Marlow, Esq. Gracin & Marlow, LLP